Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T59328
|
||||
Former ID |
TTDS00355
|
||||
Target Name |
Epidermal growth factor receptor
|
||||
Gene Name |
EGFR
|
||||
Synonyms |
EGFR-TK; Epidermal growth factor receptor ErbB-1; Epidermal growth factor receptor-tyrosine kinase; Receptor protein-tyrosine kinase ErbB-1; Proto-oncogene c-ErbB-1; EGFR
|
||||
Target Type |
Successful
|
||||
Disease | Adult primary hepatocellular carcinoma [ICD10: C22] | ||||
Advanced cancers [ICD9: 140-229; ICD10: C00-C96] | |||||
Brain cancer [ICD9: 191, 225.0; ICD10: C71, D33] | |||||
Brain cancer; Glioblastoma multiforme [ICD9:191, 225.0; ICD10: C71, D33] | |||||
Breast cancer [ICD9: 174, 175; ICD10: C50] | |||||
Colon cancer; Glioma; Breast cancer; Head and neck cancer [ICD9: 140-149, 140-229, 183, 191; ICD10: C00-C96, C07-C14, C32, C33, C56, C71] | |||||
Chronic pain [ICD9: 338.2,780; ICD10: R52.1-R52.2, G89] | |||||
Colorectal cancer [ICD9: 153, 154; ICD10: C18-C21] | |||||
Cancer [ICD9: 140-229; ICD10: C00-C96] | |||||
Chronic lymphocytic leukaemia [ICD10: C91] | |||||
Colorectal cancer; Squamous Non-small-cell lung cancer [ICD9:153, 154, 140-229, 162, 204.0; ICD10: C18-C21, C33, C33-C34, C34, C91.0] | |||||
Cryptosporidium infection [ICD10: A07.2] | |||||
Cerebrovascular ischaemia [ICD9: 434.91; ICD10: I61-I63] | |||||
Colorectal cancer; Head and neck cancer [ICD9: 140-149, 153, 154; ICD10: C18-C21, C07-C14, C32-C33] | |||||
Diabetic foot ulcer [ICD9: 707; ICD10: L88-L89] | |||||
Esophageal cancer [ICD9: 150; ICD10: C15] | |||||
Gastrointestinal disease [ICD10: K00-K93] | |||||
Glioma [ICD9: 191; ICD10: C71] | |||||
Gastric cancer; Non-small cell lung cancer [ICD9:151; ICD10: C16, C33-C34] | |||||
Glioblastoma multiforme [ICD9: 191; ICD10: C71] | |||||
Gastric cancer [ICD9: 151; ICD10: C16] | |||||
Head and neck cancer [ICD9: 140-149, 140-229; ICD10: C07-C14, C32-C33] | |||||
Head and neck squamous cell carcinoma [ICD9: 199; ICD10: C44] | |||||
Inflammatory breast cancer [ICD9: 174, 175; ICD10: C50] | |||||
Ischemia [ICD9: 459.89; ICD10: I99.8] | |||||
Locally advanced head and neck cancer [ICD9: 140-149; ICD10: C07-C14, C32, C33] | |||||
Lung cancer [ICD9: 162; ICD10: C33-C34] | |||||
Lymphoma [ICD9: 202.8, 208.9; ICD10: C81-C86] | |||||
Melanoma [ICD9: 172; ICD10: C43] | |||||
Metastatic colorectal cancer [ICD9: 153, 154; ICD10: C18-C21] | |||||
Metastatic epithelial tumors [ICD9: 140-199; ICD10: C00-C75, C7A, C7B] | |||||
Malignant tumor [ICD9: 140-199; ICD10: C00-C75, C7A, C7B] | |||||
Non-small cell lung cancer; Metastatic colorectal cancer [ICD9:153, 154; ICD10: C33-C34, C18-C21] | |||||
Non-small cell lung cancer [ICD10: C33-C34] | |||||
Ovarian cancer [ICD9: 183; ICD10: C56] | |||||
Pancreatic cancer [ICD9: 140-199, 140-229, 157, 210-229; ICD10: C25] | |||||
Psoriasis [ICD9: 696; ICD10: L40] | |||||
Recurrent squamous cell carcinoma of the hypopharynx [ICD10: D37] | |||||
Refractory breast cancer [ICD9: 174, 175; ICD10: C50] | |||||
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
Urethral cancer; Bladder cancer; Ovarian cancer; Prostate cancer; Breast cancer [ICD9: 140-229, 174, 175, 183, 188; ICD10: C50, C56, C67] | |||||
Vulnerary [ICD10: S00-T98] | |||||
Unspecified [ICD code not available] | |||||
Function |
Receptor for egf, but also for other members of the egf family, as tgf-alpha, amphiregulin, betacellulin, heparin-binding egf-like growth factor, gp30 and vaccinia virus growth factor. Is involved in the control of cell growth and differentiation.
|
||||
BioChemical Class |
Kinase
|
||||
Target Validation |
T59328
|
||||
UniProt ID | |||||
EC Number |
EC 2.7.10.1
|
||||
Sequence |
MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV
VLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA VLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF QNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC TGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV VTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK NCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF ENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL FGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN LLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV ALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS GAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI CLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA RNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY GVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK FRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ QGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED SIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN TVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV APQSSEFIGA |
||||
Drugs and Mode of Action | |||||
Drug(s) | BIBW 2992 | Drug Info | Approved | Non-small cell lung cancer | [529823], [541010] |
Cetuximab | Drug Info | Approved | Colorectal cancer | [527466], [541939] | |
DWP-401 | Drug Info | Approved | Diabetic foot ulcer | [536297] | |
Epidermal growth factor | Drug Info | Approved | Vulnerary | [551871] | |
Erlotinib | Drug Info | Approved | Non-small cell lung cancer | [468098], [527466] | |
Gefitinib | Drug Info | Approved | Cancer | [468104], [536223] | |
HEGF | Drug Info | Approved | Diabetic foot ulcer | [536297] | |
Lapatinib | Drug Info | Approved | Breast cancer | [538586], [541034] | |
Necitumumab | Drug Info | Approved | Colorectal cancer; Squamous Non-small-cell lung cancer | [522790], [542964] | |
Panitumumab | Drug Info | Approved | Colorectal cancer | [528715], [541940] | |
SKI-758 | Drug Info | Approved | Ischemia | [532210], [551871] | |
Tyverb/Tykerb | Drug Info | Approved | Refractory breast cancer | [538585] | |
Vandetanib | Drug Info | Approved | Solid tumours | [531783], [541055] | |
Icotinib hydrochloride | Drug Info | Registered | Non-small cell lung cancer | [525134], [542624], [550337] | |
AZD9291 | Drug Info | Phase 3 | Melanoma | [525278], [542692] | |
Bevacizumab + Erlotinib | Drug Info | Phase 3 | Non-small cell lung cancer; Metastatic colorectal cancer | [553819], [554242] | |
CO-1686 | Drug Info | Phase 3 | Non-small cell lung cancer | [525036], [542882] | |
Dacomitinib | Drug Info | Phase 3 | Non-small cell lung cancer | [523496], [542446] | |
DE-766 | Drug Info | Phase 3 | Gastric cancer; Non-small cell lung cancer | [550580], [550582] | |
Erlotinib | Drug Info | Phase 3 | Pancreatic cancer | [468098], [536361] | |
Gefitinib | Drug Info | Phase 3 | Head and neck cancer | [468104], [536223] | |
HKI-272 | Drug Info | Phase 3 | Breast cancer | [548009] | |
Rindopepimut | Drug Info | Phase 3 | Brain cancer; Glioblastoma multiforme | [523703] | |
Tyverb/Tykerb | Drug Info | Phase 3 | Gastric cancer | [538585] | |
Zalutumumab | Drug Info | Phase 3 | Head and neck cancer | [521892] | |
Indium-111 | Drug Info | Phase 2/3 | Solid tumours | [521975] | |
ABT-414 | Drug Info | Phase 2 | Glioblastoma multiforme | [542886], [549318] | |
ABX-EGF | Drug Info | Phase 2 | Discovery agent | [521640] | |
ASP8273 | Drug Info | Phase 2 | Non-small cell lung cancer | [525268] | |
Bevacizumab + Erlotinib | Drug Info | Phase 2 | Adult primary hepatocellular carcinoma | [523055], [553932], [554003], [555115], [555445], [555446] | |
BMS-599626 | Drug Info | Phase 2 | Solid tumours | [523940], [542630] | |
BMS-690514 | Drug Info | Phase 2 | Chronic pain | [528940] | |
CetuGEX | Drug Info | Phase 2 | Cancer | [531354] | |
CI-1033 | Drug Info | Phase 2 | Lymphoma | [525738], [541018] | |
Erlotinib | Drug Info | Phase 2 | Colon cancer; Glioma; Breast cancer; Head and neck cancer | [468098], [536361] | |
Gefitinib | Drug Info | Phase 2 | Urethral cancer; Bladder cancer; Ovarian cancer; Prostate cancer; Breast cancer | [468104], [536223] | |
HER1-VSSP vaccine | Drug Info | Phase 2 | Cancer | [525364], [528312] | |
HM-78136B | Drug Info | Phase 2 | Solid tumours | [524875], [542826] | |
Matuzumab | Drug Info | Phase 2 | Gastric cancer | [521578] | |
MEHD-7945A | Drug Info | Phase 2 | Solid tumours | [523994] | |
MEHD7945A | Drug Info | Phase 2 | Colorectal cancer; Head and neck cancer | [523994], [889373] | |
Panitumumab | Drug Info | Phase 2 | Locally advanced head and neck cancer | [538382], [541940] | |
Pazopanib + Tyverb/Tykerb | Drug Info | Phase 2 | Inflammatory breast cancer | [532156] | |
Pelitinib | Drug Info | Phase 2 | Lymphoma | [521571], [542627] | |
SYM-004 | Drug Info | Phase 2 | Head and neck cancer | [524673] | |
TT-100 | Drug Info | Phase 2 | Non-small cell lung cancer | [548064] | |
Tyverb/Tykerb | Drug Info | Phase 2 | Head and neck squamous cell carcinoma | [538585] | |
VATALANIB | Drug Info | Phase 2 | Solid tumours | [521851], [541046] | |
Bevacizumab + Erlotinib | Drug Info | Phase 1/2 | Recurrent squamous cell carcinoma of the hypopharynx | [553734] | |
EGF816 | Drug Info | Phase 1/2 | Non-small cell lung cancer | [524707] | |
EMD 55900 | Drug Info | Phase 1/2 | Glioma | [534148] | |
SN-32793 | Drug Info | Phase 1/2 | Non-small cell lung cancer | [523961] | |
Varlitinib | Drug Info | Phase 1/2 | Breast cancer | [522608], [542628] | |
S-222611 | Drug Info | Phase 1b | Malignant tumor | [551683] | |
AMG 595 | Drug Info | Phase 1 | Glioblastoma multiforme | [547942] | |
Anti-HER3/EGFR DAF | Drug Info | Phase 1 | Metastatic epithelial tumors | [550794] | |
AST-1306 | Drug Info | Phase 1 | Cancer | [549107] | |
BIBX-1382 | Drug Info | Phase 1 | Chronic lymphocytic leukaemia | [521457], [542629] | |
Cipatinib | Drug Info | Phase 1 | Cancer | [523370] | |
CUDC-101 | Drug Info | Phase 1 | Solid tumours | [533101] | |
HER-2/HER-1 vaccine | Drug Info | Phase 1 | Solid tumours | [533315] | |
IMGN289 | Drug Info | Phase 1 | Solid tumours | [524477] | |
JNJ-26483327 | Drug Info | Phase 1 | Cancer | [522319] | |
LY3164530 | Drug Info | Phase 1 | Advanced cancers | [889401] | |
MR1-1 | Drug Info | Phase 1 | Brain cancer | [522845] | |
111In-hEGF | Drug Info | Preclinical | Breast cancer | [528222], [533321] | |
EGFR/IGFR tandem adnectin | Drug Info | Preclinical | Cancer | [548559] | |
PKI166 | Drug Info | Discontinued in Phase 2 | Esophageal cancer | [542625], [547182] | |
RG7160 | Drug Info | Discontinued in Phase 2 | Metastatic colorectal cancer | [548810] | |
AZD4769 | Drug Info | Discontinued in Phase 1 | Solid tumours | [548344] | |
PD-153035 | Drug Info | Discontinued in Phase 1 | Psoriasis | [545893] | |
TAK165 | Drug Info | Discontinued in Phase 1 | Cancer | [541276], [547786] | |
AZD-9935 | Drug Info | Terminated | Solid tumours | [547683] | |
CGP-52411 | Drug Info | Terminated | Cancer | [545834] | |
CGP-53353 | Drug Info | Terminated | Discovery agent | [468226], [546079] | |
Heparin-EGF-like factor | Drug Info | Terminated | Gastrointestinal disease | [533768], [533866] | |
Inhibitor | (3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine | Drug Info | [533683] | ||
(3-Bromo-phenyl)-quinazolin-4-yl-amine | Drug Info | [534127] | |||
(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin | Drug Info | [530002] | |||
(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate | Drug Info | [551353] | |||
10-hydroxy-18-methoxybetaenone | Drug Info | [525806] | |||
2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile | Drug Info | [528244] | |||
2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile | Drug Info | [528244] | |||
2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile | Drug Info | [551353] | |||
2-cyano-3-(3,4-dihydroxyphenyl)acrylamide | Drug Info | [551353] | |||
2-methoxy-4-(2-nitrovinyl)phenol | Drug Info | [551353] | |||
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione | Drug Info | [528032] | |||
3,4-diphenyl-1H-pyrrole-2,5-dione | Drug Info | [528032] | |||
3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one | Drug Info | [525445] | |||
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione | Drug Info | [528032] | |||
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione | Drug Info | [528032] | |||
3-Pyridin-4-yl-quinoline-6,7-diol | Drug Info | [533872] | |||
4-(2-nitroprop-1-enyl)benzene-1,2-diol | Drug Info | [551353] | |||
4-(2-nitrovinyl)benzene-1,2-diol | Drug Info | [551353] | |||
4-(2-nitrovinyl)phenol | Drug Info | [551353] | |||
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline | Drug Info | [551331] | |||
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline | Drug Info | [551331] | |||
4-(3-Bromo-phenylamino)-quinazoline-6,7-diol | Drug Info | [534127] | |||
4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid | Drug Info | [551353] | |||
4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline | Drug Info | [529134] | |||
4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide | Drug Info | [527849] | |||
4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline | Drug Info | [529046] | |||
4557W | Drug Info | [526072] | |||
5,6-Bis-p-tolylamino-isoindole-1,3-dione | Drug Info | [533915] | |||
5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide | Drug Info | [527849] | |||
6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline | Drug Info | [529046] | |||
6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline | Drug Info | [529046] | |||
6,7-diethoxy-4-styrylquinazoline | Drug Info | [529046] | |||
6,7-dimethoxy-4-(2-phenylethynyl)quinazoline | Drug Info | [529046] | |||
6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline | Drug Info | [529046] | |||
6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline | Drug Info | [529046] | |||
6,7-dimethoxy-N-m-tolylquinazolin-4-amine | Drug Info | [529935] | |||
6-chloro-N-(3-chlorophenyl)quinazolin-4-amine | Drug Info | [530473] | |||
AG 112 | Drug Info | [533080] | |||
AG 9 | Drug Info | [533080] | |||
AG-213 | Drug Info | [529134] | |||
AG-538 | Drug Info | [551353] | |||
ASP8273 | Drug Info | [549984] | |||
AZD4769 | Drug Info | [550288] | |||
AZD9291 | Drug Info | [532797] | |||
Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine | Drug Info | [534127] | |||
Benzyl-quinazolin-4-yl-amine | Drug Info | [533683] | |||
Bevacizumab + Erlotinib | Drug Info | [551607] | |||
BIBW 2992 | Drug Info | [550386] | |||
BMS-599626 | Drug Info | [530678], [536474] | |||
BMS-690514 | Drug Info | [530732] | |||
BPIQ-I | Drug Info | [534127] | |||
CGP-52411 | Drug Info | [534180] | |||
CGP-53353 | Drug Info | [533915] | |||
CI-1033 | Drug Info | [536474] | |||
CL-387785 | Drug Info | [529935] | |||
Cochliobolic acid | Drug Info | [534313] | |||
compound 38 | Drug Info | [532836] | |||
compound 56 | Drug Info | [534095] | |||
EGF816 | Drug Info | [532489] | |||
EGFR inhibitor | Drug Info | [529213] | |||
EGFR/IGFR tandem adnectin | Drug Info | [550011] | |||
Epitinib | Drug Info | [543485] | |||
Erlotinib | Drug Info | [537629] | |||
Gefitinib | Drug Info | [535899], [535901] | |||
HDS-029 | Drug Info | [528037] | |||
HKI-272 | Drug Info | [528774] | |||
HM-61713B | Drug Info | [543485] | |||
HM-78136B | Drug Info | [531542] | |||
HTS-00213 | Drug Info | [529935] | |||
HTS-02876 | Drug Info | [529935] | |||
HTS-05058 | Drug Info | [529213] | |||
IMGN289 | Drug Info | [544376] | |||
JNJ-26483327 | Drug Info | [550422] | |||
Lapatinib | Drug Info | [536331], [537224] | |||
LAVENDUSTIN A | Drug Info | [533837] | |||
MDP-01 | Drug Info | [543485] | |||
MT-062 | Drug Info | [543485] | |||
N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine | Drug Info | [534127] | |||
N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine | Drug Info | [526895] | |||
N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine | Drug Info | [533683] | |||
N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine | Drug Info | [534120] | |||
N-(4-(phenylamino)quinazolin-6-yl)acrylamide | Drug Info | [528707] | |||
N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide | Drug Info | [525502] | |||
N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide | Drug Info | [525502] | |||
N4-(3-chlorophenyl)quinazoline-4,6-diamine | Drug Info | [528809] | |||
N4-(3-methylphenyl)-4,6-quinazolinediamine | Drug Info | [528236] | |||
NRC-2694 | Drug Info | [543485] | |||
ON-128 | Drug Info | [543485] | |||
OSI-75 | Drug Info | [535318] | |||
Pazopanib + Tyverb/Tykerb | Drug Info | [550963] | |||
PD-0166326 | Drug Info | [525862] | |||
PD-0173956 | Drug Info | [525862] | |||
PD-0180970 | Drug Info | [525862] | |||
PD-158780 | Drug Info | [534120] | |||
PD-168393 | Drug Info | [528707] | |||
PD182905 | Drug Info | [535233] | |||
PP121 | Drug Info | [529744] | |||
RG-50810 | Drug Info | [551353] | |||
RM-6427 | Drug Info | [543485] | |||
Ro-4396686 | Drug Info | [528018] | |||
S-222611 | Drug Info | [551683] | |||
SKI-758 | Drug Info | [528584] | |||
SN-32793 | Drug Info | [543485] | |||
TAK165 | Drug Info | [536474] | |||
Theliatinib | Drug Info | [543485] | |||
TT-100 | Drug Info | [549834] | |||
TYRPHOSTIN AG-1478 | Drug Info | [525445] | |||
Tyverb/Tykerb | Drug Info | [550963] | |||
Vandetanib | Drug Info | [536474], [550288] | |||
VATALANIB | Drug Info | [528774] | |||
WHI-P154 | Drug Info | [529228] | |||
WZ-3146 | Drug Info | [543485] | |||
Modulator | 111In-hEGF | Drug Info | [525767] | ||
AGT-2000 | Drug Info | [543485] | |||
AL-6802 | Drug Info | [543485] | |||
AMG 595 | Drug Info | [533230] | |||
Anti-HER3/EGFR DAF | Drug Info | ||||
AST-1306 | Drug Info | [531575] | |||
Cipatinib | Drug Info | [1572591] | |||
CO-1686 | Drug Info | [533226] | |||
CUDC-101 | Drug Info | [533101] | |||
DE-766 | Drug Info | [543485] | |||
Epidermal growth factor | Drug Info | [543485] | |||
Heparin-EGF-like factor | Drug Info | [533768], [533866] | |||
Imaging-theranostic nanoemulsion agents | Drug Info | [543485] | |||
LA22-radioimmunoconjugates | Drug Info | [543485] | |||
LY3164530 | Drug Info | [889442] | |||
MEHD-7945A | Drug Info | [1572591] | |||
MEHD7945A | Drug Info | [889442] | |||
MG-111 | Drug Info | ||||
MR1-1 | Drug Info | [550395] | |||
Necitumumab | Drug Info | [531296] | |||
PD-153035 | Drug Info | ||||
Pelitinib | Drug Info | ||||
PF 5208766 | Drug Info | ||||
PKI166 | Drug Info | ||||
RG7160 | Drug Info | [532140] | |||
Rindopepimut | Drug Info | [531296] | |||
Small-molecule cetuximab binding mimics | Drug Info | [543485] | |||
SYM-011 | Drug Info | [543485] | |||
TGF alpha | Drug Info | [543485] | |||
Varlitinib | Drug Info | [1572591] | |||
Antagonist | AZD-9935 | Drug Info | [550140] | ||
BIBX-1382 | Drug Info | [526329] | |||
Dacomitinib | Drug Info | [543485] | |||
EDP-13 | Drug Info | [543485] | |||
Icotinib hydrochloride | Drug Info | [531288] | |||
IPS-01003 | Drug Info | [543485] | |||
RX-1792 | Drug Info | [543485] | |||
Activator | DWP-401 | Drug Info | [536297] | ||
HEGF | Drug Info | [536297] | |||
Suppressor | Panitumumab | Drug Info | [537616] | ||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
Pathways | |||||
KEGG Pathway | MAPK signaling pathway | ||||
ErbB signaling pathway | |||||
Ras signaling pathway | |||||
Rap1 signaling pathway | |||||
Calcium signaling pathway | |||||
Cytokine-cytokine receptor interaction | |||||
HIF-1 signaling pathway | |||||
FoxO signaling pathway | |||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
Dorso-ventral axis formation | |||||
Focal adhesion | |||||
Adherens junction | |||||
Gap junction | |||||
Regulation of actin cytoskeleton | |||||
GnRH signaling pathway | |||||
Estrogen signaling pathway | |||||
Oxytocin signaling pathway | |||||
Epithelial cell signaling in Helicobacter pylori infection | |||||
Hepatitis C | |||||
Pathways in cancer | |||||
Proteoglycans in cancer | |||||
MicroRNAs in cancer | |||||
Pancreatic cancer | |||||
Endometrial cancer | |||||
Glioma | |||||
Prostate cancer | |||||
Melanoma | |||||
Bladder cancer | |||||
Non-small cell lung cancer | |||||
Central carbon metabolism in cancer | |||||
Choline metabolism in cancer | |||||
NetPath Pathway | IL4 Signaling Pathway | ||||
EGFR1 Signaling Pathway | |||||
PANTHER Pathway | Cadherin signaling pathway | ||||
EGF receptor signaling pathway | |||||
Pathway Interaction Database | LPA receptor mediated events | ||||
Signaling events mediated by PTP1B | |||||
Arf6 signaling events | |||||
Signaling events mediated by TCPTP | |||||
Thromboxane A2 receptor signaling | |||||
SHP2 signaling | |||||
Regulation of Telomerase | |||||
EGF receptor (ErbB1) signaling pathway | |||||
EGFR-dependent Endothelin signaling events | |||||
Posttranslational regulation of adherens junction stability and dissassembly | |||||
Direct p53 effectors | |||||
ErbB1 downstream signaling | |||||
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||||
E-cadherin signaling in keratinocytes | |||||
ErbB receptor signaling network | |||||
Internalization of ErbB1 | |||||
Stabilization and expansion of the E-cadherin adherens junction | |||||
a6b1 and a6b4 Integrin signaling | |||||
Syndecan-3-mediated signaling events | |||||
Reactome | Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | ||||
SHC1 events in ERBB2 signaling | |||||
PLCG1 events in ERBB2 signaling | |||||
PIP3 activates AKT signaling | |||||
GRB2 events in EGFR signaling | |||||
GAB1 signalosome | |||||
SHC1 events in EGFR signaling | |||||
EGFR downregulation | |||||
GRB2 events in ERBB2 signaling | |||||
PI3K events in ERBB2 signaling | |||||
EGFR Transactivation by Gastrin | |||||
Constitutive Signaling by Aberrant PI3K in Cancer | |||||
Constitutive Signaling by EGFRvIII | |||||
RAF/MAP kinase cascade | |||||
WikiPathways | ErbB Signaling Pathway | ||||
Regulation of Actin Cytoskeleton | |||||
EGF/EGFR Signaling Pathway | |||||
MAPK Signaling Pathway | |||||
Focal Adhesion | |||||
Aryl Hydrocarbon Receptor Pathway | |||||
Extracellular vesicle-mediated signaling in recipient cells | |||||
TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer | |||||
Cytodifferentiation (Part 3 of 3) | |||||
Bladder Cancer | |||||
Induction (Part 1 of 3) | |||||
Signaling by ERBB4 | |||||
Signaling by ERBB2 | |||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
PIP3 activates AKT signaling | |||||
Nanoparticle-mediated activation of receptor signaling | |||||
Aryl Hydrocarbon Receptor | |||||
Spinal Cord Injury | |||||
Integrated Pancreatic Cancer Pathway | |||||
Gastric cancer network 2 | |||||
AGE/RAGE pathway | |||||
Signaling Pathways in Glioblastoma | |||||
Arylhydrocarbon receptor (AhR) signaling pathway | |||||
miR-targeted genes in muscle cell - TarBase | |||||
miR-targeted genes in lymphocytes - TarBase | |||||
miR-targeted genes in epithelium - TarBase | |||||
Integrated Breast Cancer Pathway | |||||
Signaling by EGFR | |||||
L1CAM interactions | |||||
References | |||||
Ref 468098 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4920). | ||||
Ref 468104 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4941). | ||||
Ref 468226 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5163). | ||||
Ref 521457 | ClinicalTrials.gov (NCT00003980) BIBX 1382 in Treating Patients With Solid Tumors. U.S. National Institutes of Health. | ||||
Ref 521571 | ClinicalTrials.gov (NCT00067548) Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer. U.S. National Institutes of Health. | ||||
Ref 521578 | ClinicalTrials.gov (NCT00073541) A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer. U.S. National Institutes of Health. | ||||
Ref 521640 | ClinicalTrials.gov (NCT00111761) Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health. | ||||
Ref 521851 | ClinicalTrials.gov (NCT00348790) Vatalanib in Treating Patients With Recurrent or Progressive Meningioma. U.S. National Institutes of Health. | ||||
Ref 521892 | ClinicalTrials.gov (NCT00382031) Zalutumumab in Patients With Non-curable Head and Neck Cancer. U.S. National Institutes of Health. | ||||
Ref 521975 | ClinicalTrials.gov (NCT00442533) Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors. U.S. National Institutes of Health. | ||||
Ref 522319 | ClinicalTrials.gov (NCT00676299) A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.. U.S. National Institutes of Health. | ||||
Ref 522608 | ClinicalTrials.gov (NCT00862524) A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer. U.S. National Institutes of Health. | ||||
Ref 522790 | ClinicalTrials.gov (NCT00981058) First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin. U.S. National Institutes of Health. | ||||
Ref 522845 | ClinicalTrials.gov (NCT01009866) Study of Immunotoxin, MR1-1. U.S. National Institutes of Health. | ||||
Ref 523055 | ClinicalTrials.gov (NCT01130519) A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer. U.S. National Institutes of Health. | ||||
Ref 523370 | ClinicalTrials.gov (NCT01301911) Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer. U.S. National Institutes of Health. | ||||
Ref 523496 | ClinicalTrials.gov (NCT01360554) ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer. U.S. National Institutes of Health. | ||||
Ref 523703 | ClinicalTrials.gov (NCT01480479) Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma. U.S. National Institutes of Health. | ||||
Ref 523940 | ClinicalTrials.gov (NCT01614522) A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1and HER-2. U.S. National Institutes of Health. | ||||
Ref 523961 | ClinicalTrials.gov (NCT01631279) A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors. U.S. National Institutes of Health. | ||||
Ref 523994 | ClinicalTrials.gov (NCT01652482) A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer. U.S. National Institutes of Health. | ||||
Ref 524477 | ClinicalTrials.gov (NCT01963715) A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors. U.S. National Institutes of Health. | ||||
Ref 524673 | ClinicalTrials.gov (NCT02083653) Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer. U.S. National Institutes of Health. | ||||
Ref 524707 | ClinicalTrials.gov (NCT02108964) A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies. U.S. National Institutes of Health. | ||||
Ref 524875 | ClinicalTrials.gov (NCT02216916) Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy. U.S. National Institutes of Health. | ||||
Ref 525036 | ClinicalTrials.gov (NCT02322281) TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy. U.S. National Institutes of Health. | ||||
Ref 525134 | ClinicalTrials.gov (NCT02404675) High Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With EGFR 21 Exon Positive. U.S. National Institutes of Health. | ||||
Ref 525268 | ClinicalTrials.gov (NCT02500927) A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations. | ||||
Ref 525278 | ClinicalTrials.gov (NCT02511106) AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. | ||||
Ref 525364 | HER1-ECD vaccination dispenses with emulsification to elicit HER1-specific anti-proliferative effects. Hum Vaccin. 2009 Mar;5(3):158-65. Epub 2009 Mar 6. | ||||
Ref 525738 | Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem. 2000 Apr 6;43(7):1380-97. | ||||
Ref 528222 | Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. J Nucl Med. 2006 Jun;47(6):1023-31. | ||||
Ref 528312 | Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer. 2006 Nov 1;119(9):2190-9. | ||||
Ref 528940 | A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res. 2007 Jul 1;67(13):6253-62. | ||||
Ref 529823 | BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs. 2008 Dec;9(12):1336-46. | ||||
Ref 531354 | Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011 May 1;11(9):777-92. Epub 2011 May 1. | ||||
Ref 532156 | A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Res Treat. 2013 Jan;137(2):471-82. | ||||
Ref 533101 | A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73. | ||||
Ref 533315 | Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines (Basel). 2015 Jul 6;3(3):519-43. | ||||
Ref 533321 | A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice. Nucl Med Biol. 2015 Aug 19. pii: S0969-8051(15)00147-X. | ||||
Ref 533768 | The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans. J Cell Sci. 1994 Sep;107 ( Pt 9):2599-608. | ||||
Ref 533866 | Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. J Biol Chem. 1994 Aug 5;269(31):20060-6. | ||||
Ref 534148 | Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Eur J Cancer. 1996 Apr;32A(4):636-40. | ||||
Ref 536223 | Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. | ||||
Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
Ref 538382 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (BLA) 125147. | ||||
Ref 538585 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059. | ||||
Ref 538586 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059. | ||||
Ref 541010 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5667). | ||||
Ref 541018 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5675). | ||||
Ref 541034 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5692). | ||||
Ref 541046 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5705). | ||||
Ref 541055 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5717). | ||||
Ref 541276 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6011). | ||||
Ref 541939 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6882). | ||||
Ref 541940 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6883). | ||||
Ref 542446 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422). | ||||
Ref 542624 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7641). | ||||
Ref 542625 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7642). | ||||
Ref 542627 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7644). | ||||
Ref 542628 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7645). | ||||
Ref 542629 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7646). | ||||
Ref 542630 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7647). | ||||
Ref 542692 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7719). | ||||
Ref 542826 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7903). | ||||
Ref 542882 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7966). | ||||
Ref 542886 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7970). | ||||
Ref 542964 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8090). | ||||
Ref 545834 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004971) | ||||
Ref 545893 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005268) | ||||
Ref 546079 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006215) | ||||
Ref 547182 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013689) | ||||
Ref 547683 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018392) | ||||
Ref 547786 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019257) | ||||
Ref 547942 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020588) | ||||
Ref 548009 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021154) | ||||
Ref 548064 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021633) | ||||
Ref 548344 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024847) | ||||
Ref 548559 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026610) | ||||
Ref 548810 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029052) | ||||
Ref 549107 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032292) | ||||
Ref 549318 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035129) | ||||
Ref 551871 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
Ref 553734 | ClinicalTrials.gov (NCT00055913) Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | ||||
Ref 553819 | ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer | ||||
Ref 553932 | ClinicalTrials.gov (NCT00287222) Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma | ||||
Ref 554003 | ClinicalTrials.gov (NCT00365391) Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer | ||||
Ref 554242 | ClinicalTrials.gov (NCT00598156) Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva | ||||
Ref 555115 | ClinicalTrials.gov (NCT02655536) Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial | ||||
Ref 555445 | Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S17-23. doi: 10.3816/CLC.2009.s.003. | ||||
Ref 555446 | Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011 May 28;377(9780):1846-54. doi: 10.1016/S0140-6736(11)60545-X. | ||||
Ref 525445 | J Med Chem. 1999 Mar 25;42(6):1018-26.Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. | ||||
Ref 525502 | J Med Chem. 1999 May 20;42(10):1803-15.Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding siteof the epidermal growth factor receptor. | ||||
Ref 525767 | A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J Nucl Med. 2000 May;41(5):903-11. | ||||
Ref 525806 | J Nat Prod. 2000 Jun;63(6):739-45.Anthraquinones and betaenone derivatives from the sponge-associated fungus Microsphaeropsis species: novel inhibitors of protein kinases. | ||||
Ref 525862 | Biochem Pharmacol. 2000 Oct 1;60(7):885-98.Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. | ||||
Ref 526072 | Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. | ||||
Ref 526329 | Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38(8):1072-80. | ||||
Ref 526895 | J Med Chem. 2003 Dec 4;46(25):5546-51.Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept. | ||||
Ref 527849 | Bioorg Med Chem Lett. 2006 Jan 15;16(2):469-72. Epub 2005 Nov 3.Acryloylamino-salicylanilides as EGFR PTK inhibitors. | ||||
Ref 528018 | Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. Epub 2006 Feb 3.Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. | ||||
Ref 528032 | J Med Chem. 2006 Feb 23;49(4):1271-81.Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. | ||||
Ref 528037 | J Med Chem. 2006 Feb 23;49(4):1475-85.Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors. | ||||
Ref 528236 | J Med Chem. 2006 Jun 15;49(12):3544-52.The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). | ||||
Ref 528244 | J Med Chem. 1991 Jun;34(6):1896-907.Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. | ||||
Ref 528312 | Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer. 2006 Nov 1;119(9):2190-9. | ||||
Ref 528584 | J Med Chem. 2006 Dec 28;49(26):7868-76.Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. | ||||
Ref 528707 | Nat Chem Biol. 2007 Apr;3(4):229-38. Epub 2007 Mar 4.Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. | ||||
Ref 528774 | Bioorg Med Chem. 2007 Jun 1;15(11):3635-48. Epub 2007 Mar 23.Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. | ||||
Ref 528809 | J Med Chem. 2007 May 31;50(11):2605-8. Epub 2007 May 2.Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship. | ||||
Ref 529046 | Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7. Epub 2007 Aug 15.Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. | ||||
Ref 529134 | Eur J Med Chem. 2008 Jul;43(7):1478-88. Epub 2007 Sep 29.Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. | ||||
Ref 529213 | Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. Epub 2007 Dec 11.A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. | ||||
Ref 529228 | The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7. Epub 2007 Dec 19. | ||||
Ref 529407 | Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell. 2008 Apr;13(4):365-73. | ||||
Ref 529744 | Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. | ||||
Ref 529935 | J Med Chem. 2009 Feb 26;52(4):964-75.Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies. | ||||
Ref 530002 | Eur J Med Chem. 2009 Sep;44(9):3471-9. Epub 2009 Feb 7.5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line. | ||||
Ref 530473 | Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. Epub 2009 Oct 9.Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. | ||||
Ref 530678 | AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs. 2011 Aug;29(4):554-61. | ||||
Ref 530732 | Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93. | ||||
Ref 531288 | Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer. 2011 Aug;73(2):195-202. | ||||
Ref 531296 | Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010 Dec;12(6):741-54. | ||||
Ref 531354 | Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011 May 1;11(9):777-92. Epub 2011 May 1. | ||||
Ref 531542 | Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012 May 15;130(10):2445-54. | ||||
Ref 531575 | AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One. 2011;6(7):e21487. | ||||
Ref 532140 | GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res. 2013 Mar 1;19(5):1126-38. | ||||
Ref 532489 | Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Dec;3(12):1404-15. | ||||
Ref 532540 | Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia. 2013 Oct;15(10):1196-206. | ||||
Ref 532797 | AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61. | ||||
Ref 532836 | Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28. | ||||
Ref 533080 | Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem. 1989 Oct;32(10):2344-52. | ||||
Ref 533101 | A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73. | ||||
Ref 533159 | Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51. | ||||
Ref 533226 | Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1700-9. | ||||
Ref 533230 | AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. Mol Cancer Ther. 2015 Jul;14(7):1614-24. | ||||
Ref 533683 | J Med Chem. 1995 Sep 1;38(18):3482-7.Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. | ||||
Ref 533768 | The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans. J Cell Sci. 1994 Sep;107 ( Pt 9):2599-608. | ||||
Ref 533837 | J Med Chem. 1994 Nov 25;37(24):4079-84.Novel antiproliferative agents derived from lavendustin A. | ||||
Ref 533866 | Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. J Biol Chem. 1994 Aug 5;269(31):20060-6. | ||||
Ref 533872 | J Med Chem. 1994 Aug 19;37(17):2627-9.5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase. | ||||
Ref 533915 | J Med Chem. 1994 Apr 1;37(7):1015-27.Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. | ||||
Ref 534095 | Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996 Jan 5;39(1):267-76. | ||||
Ref 534120 | J Med Chem. 1996 Apr 26;39(9):1823-35.Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. | ||||
Ref 534127 | J Med Chem. 1996 Feb 16;39(4):918-28.Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. | ||||
Ref 534180 | Retinoic acid-induced RB (retinoblastoma) hypophosphorylation enhanced by CGP 52411 (4,5-dianilinophthalimide), an EGF family tyrosine kinase receptor inhibitor. Eur J Cell Biol. 1996 Apr;69(4):327-34. | ||||
Ref 534313 | J Nat Prod. 1997 Jan;60(1):6-8.Cochliobolic acid, a novel metabolite produced by Cochliobolus lunatus, inhibits binding of TGF-alpha to the EGF receptor in a SPA assay. | ||||
Ref 535233 | Growth factors and their receptors: new targets for prostate cancer therapy. Urology. 2001 Aug;58(2 Suppl 1):114-22. | ||||
Ref 535318 | Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 2001;6(6):517-37. | ||||
Ref 535397 | Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002 Feb;29(1 Suppl 4):27-36. | ||||
Ref 535418 | Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002 Mar 1;94(5):1593-611. | ||||
Ref 535602 | Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol. 2002 Oct;29(5 Suppl 14):31-7. | ||||
Ref 535628 | Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther. 2002 May;1(7):507-14. | ||||
Ref 535899 | Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Semin Cancer Biol. 2004 Feb;14(1):33-40. | ||||
Ref 535901 | Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72. | ||||
Ref 536331 | Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. Epub 2006 Nov 28. | ||||
Ref 536474 | A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. | ||||
Ref 537224 | Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. | ||||
Ref 537616 | Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2009 Jul 16. | ||||
Ref 537629 | Quantitative Prediction of Fold Resistance for Inhibitors of EGFR. Biochemistry. 2009 Jul 23. | ||||
Ref 543485 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). | ||||
Ref 544371 | Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278. | ||||
Ref 544376 | World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA. MAbs. 2014 January 1; 6(1): 18-29. | ||||
Ref 549834 | BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009. | ||||
Ref 549984 | Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC, Journal of Clinical Oncology, Vol 33, No 15_suppl (May 20 Supplement), 2015: 8083. | ||||
Ref 551331 | A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). | ||||
Ref 551353 | Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60. | ||||
Ref 889442 | Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. doi: 10.1038/nrd4478. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.